Synaptogenix (Synaptogenix) EBIT per Share : $-13.41 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Synaptogenix EBIT per Share?

Synaptogenix's EBIT per Share for the three months ended in Mar. 2024 was $-1.63. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-13.41.

During the past 3 years, the average EBIT per Share Growth Rate was 56.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Synaptogenix's EBIT per Share or its related term are showing as below:

SNPX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 42.9 Med: 49.9 Max: 56.9
Current: 56.9

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Synaptogenix was 56.90% per year. The lowest was 42.90% per year. And the median was 49.90% per year.

SNPX's 3-Year EBIT Growth Rate is ranked better than
94.94% of 1305 companies
in the Biotechnology industry
Industry Median: 3.4 vs SNPX: 56.90

Synaptogenix's EBIT for the three months ended in Mar. 2024 was $-1.69 Mil.

Synaptogenix EBIT per Share Historical Data

The historical data trend for Synaptogenix's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synaptogenix EBIT per Share Chart

Synaptogenix Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-310.26

-223.12

-62.78

-57.63

-17.84

Synaptogenix Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial														-9.74	-6.22	-3.34	-2.21	-1.63

Synaptogenix EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Synaptogenix's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.314	/	0.466
=	-17.84

Synaptogenix's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.691	/	1.037
=	-1.63

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.41

Synaptogenix (NAS:SNPX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Synaptogenix EBIT per Share Related Terms

Thank you for viewing the detailed overview of Synaptogenix's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Synaptogenix (Synaptogenix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synaptogenix Inc (NAS:SNPX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036

Website

https://www.synaptogen.com

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Executives

Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Robert Weinstein	officer: Chief Financial Officer	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Bruce Bernstein	director	780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
William S. Singer	director	C/O KIRKLAND & ELLIS LLP, 300 NORTH LASALLE, CHICAGO IL 60654
Daniel L. Alkon	director, officer: Chief Scientific Officer	C/O NEUROTROPE, INE., 205 EAST 42ND STREET - 20TH FLOOR, NEW YORK NY 10017
Alan J Tuchman	director, officer: Chief Executive Officer	18 SYCAMORE ROAD, MAHOPAC NY 10541
George Perry	director	C/O NEUROTROPE, INC., 205 EAST 42ND STREET, 17TH FLOOR, NEW YORK NY 10010